Enzyme Inhibitors from Gorgonians and Soft Corals
January 2023
in “
Marine Drugs
”
TLDR Marine compounds from gorgonians and soft corals show promise for drug development, especially for chronic disorders.
The review examined enzyme inhibitors from gorgonians and soft corals, emphasizing their potential in biomedicine and industry. It identified 127 inhibitor molecules, mainly terpenes and terpenoids, from over 50 reports, with soft corals being the primary source. These inhibitors targeted enzymes like hydrolases and transferases, with notable targets including PTP1B, relevant for type 2 diabetes, obesity, and breast cancer. Despite structural studies, enzymological characterization was often lacking, prompting recommendations for using STRENDA guidelines to improve reporting. The study highlighted the potential of marine-derived compounds in drug development, particularly for chronic disorders, and emphasized the need for standardized procedures to enhance research quality.